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Abstract  
Pharmacokinetic features of benzophenone-3 
after dermal application in humans 
Lee, Sujin
Department of Environmental Health
Graduate School of Public Health
Seoul National University
Benzophenone-3 (BP-3) is a component that blocks ultraviolet rays. It is 
mainly used in sunscreen agents and functional cosmetics, and is mostly 
exposed through the skin. several studies have reported the possibility of 
endocrine disturbance. Whereas pharmacokinetic studies on BP-3 have been 
reported in animal, it is not well known to the fate of BP-3 in human body 
following dermal exposure. The aim of this study is to determine 
pharmacokinetic characteristics of BP-3 in male subjects following single 
dermal application of 1 mg/cm2 of deuterium labeled BP-3. 
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Blood and urine were collected for 72 hours and analyzed BP-3 and its 
metabolites using UPLC-MS/MS. In blood, after peak time eliminated 
decline two distinct phases in time-profile, while the metabolites followed 
first-order kinetics. Based on time-profiles, a multi-compartmental model 
constructed and validated. As a results, unconjugated BP-3 concentration in 
serum was lower than conjugated BP-3 concentration in serum. But it was 
similar to that of total BP-1 concentration in serum. Almost of the BP-3 and 
BP-1 in urine undergo conjugation or demethylation. And the fraction of 
urinary excretion for conjugated BP-3 (0.76 ± 0.19%) was 4-fold upper than 
total BP-1 (0.19 ± 0.13%), which was approximately 580-fold upper than 
unconjugated BP-3 (0.0013 ± 0.0005%). This study provides information on 
absorption, distribution, metabolism and elimination of BP-3 in human body 
and the pharmacokinetic model can be utilized for estimating exposure dose 
of BP-3, contributing to more realistic exposure assessment in the Korean 
population based upon biomonitoring data. 
Keywords: bezophenone-3, dermal application, pharmacokinetic model,
the fraction of urinary excretion, absorption · distribution · 
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. Introduction 
The toxic potential of UV (ultra violet light) filters, used in a variety of 
sunscreen and personal care products to attenuate the negative effects of 
harmful UV radiation on skin and hair, has been a concern. Benzophenone-
3 (BP-3, 2-hydroxy-4-methoxybenzophenone, oxybenzone) is one of the 
most widely used BP type UV filters and has been available as a 
sunscreen agent for over 40 years (Kim and Choi, 2014). It is found in 
over 1,500 products at concentrations up to 0.15% (EWG, 2016). In the 
U.S., BP-3 is a commonly used sunscreen agent (EWG, 2012). Because of 
the extensive use of BP-3 in personal care products, human exposure to this 
compound is widespread. BP-3 was found in >95% of urine samples 
collected from the U.S. general population (Calafat et al., 2008; Ye et al., 
2005; Wolff et al., 2007), at concentrations ranging from 0.4 to 21700 ng/mL. 
The application of some personal care products that contain UV filters on the 
skin and frequent reapplication can increase the systemic absorption (Janjua 
et al., 2008; Jiang et al., 1999; León et al., 2010). BP-3 arose predominately 
after studies reported a systematic absorption of BP-3 in humans at a rate of 
up 1% to 2% after dermal application (Wang et al., 2011; Krause et al., 2012). 
Studies have linked endocrine-disrupting chemicals, which includes BP-3,
with adverse birth outcomes via alterations in sex hormone activity during 
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development. BP-3 was shown to be weakly estrogenic in in vitro and in vivo 
(Fent et al., 2008; Schlumpf et al., 2001) and antiandrogenic in in vitro 
studies (Schreurs et al., 2005). Recent study also reported a significant 
association between exposure to BP-3 and an estrogen mediated disease, 
endometriosis in women (Kunisue et al., 2012).
BP-3 is rapidly absorbed from the intact skin and from gastrointestinal 
tract and demethylated and excreted in the urine in human (Wang et al., 
2015). The metabolic pathways of BP-3 in human are shown in Fig. 1. 
BP-3 is metabolized to benzophenone-1 (BP-1, or 2,4-
dihydroxybenzophenone) and benzophenone-8 (BP-8 or 2,2 OH-4MeO-BP 
or 2,2 -dihydroxy-4-methoxybenzophenone). BP-1 is formed via O-
demethylation of the methoxy side chain on ring A of BP-3, whereas BP-8 is 
formed via the aromatic hydroxylation of ring B at the ortho position. A small 
portion of BP-1 can be further converted into THB via the aromatic 
hydroxylation of ring A at the meta position. It is noteworthy that the 
metabolite, BP-1, possesses greater estrogenic activity than does BP-3
(Kawamura et al., 2003, 2005; Nakagawa and Suzuki, 2002; Suzuki et al., 
2005; Takatori et al., 2003).
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Figure 1. Metabolic pathways of benzophenone-3 in human. Adapted from
Kim and choi (2014). Abbreviation: THB - 2,3,4-Trihydroxybenzophenone; 
SULTs - sulfotransferases; UGT - glucuronosyltransferases.
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Several studies on the pharmacokinetics of BP-3 in animal have been 
reported (Jeon et al., 2008; Okereke et al., 1994), But research on human is 
quite limited. After topical application of BP-3 in female and male volunteers, 
systemic uptakes were confirmed (Gonzalez et al. 2002). And urinary 
excretion factor (Fue) for BP-3 were reported. However, regarding to Fue, it 
should be assumed that a simple steady-state kinetics for BP-3. Any kinetic 
information for BP-3 had been not suggested based on human data. Another
studies investigated to BP-3 in blood, also any kinetic information for BP-3
and its metabolites had been not reported (janjua et al., 2008; tarazona et al.,
2013).
Therefore, the elaborate study is required on the kinetics for BP-3 in 
humans. To the best of our knowledge, there are no pharmacokinetic study
to simultaneously quantitate unconjugated and total (conjugated and 
unconjugated) BP-3 and its metabolites BP-1 in human urine and blood.
The objective of the study is to determine pharmacokinetic characteristics 
of BP-3 and its metabolite in volunteers after a single dermal application
with a multi-compartment model. And then, it is possible to explain that how 
it was absorbed, distributed, metabolized and excreted in human body.    
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. Materials and methods
1. Chemicals and Reagents
2-Hydroxy-4-methoxybenzophenone-2’,3’,4’,5’,6’-d5 (BP-3-d5, 99%) and 
2,4-Dihydroxybenzophenone-2’,3’,4’,5’,6’-d5 (BP-1-d5, 98.8%) were 
purchased from CDN Isotopes Inc. (Point-Claire, Quebec). 13C6-2-Hydroxy-4-
methoxybenzophenone (13C6-BP-3, 99%) was used as internal standard and 
obtained from Cambridge Isotope Laboratories Inc. (Tewksbury, MA).
Acetonitrile, methanol, and water (HPLC grade) were purchased from J. T. 
Baker (Center Valley, PA) and acetic acid (HPLC grade) was obtained from 
Fisher Chemical Co. (Fair Lawn, NJ). Formic acid (98+%) were purchased 
from Acros organics Co. (Morris Plains, NJ) and ammonium acetate (
-Glucuronidase and sulfatase from Helix pomatia were purchased 
from Sigma-Aldrich (St. Louis, MO).
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2. Study Design and Sample Collection
Five volunteers participated in the study. All participants were male and 
lived in Seoul, Korea. A single application with a cream containing 5% 
deuterated 2-Hydroxy-4-methoxybenzophenone (BP-3-d5) to the right or left 
forearm for an hour. 200 mg for a forearm area of 200 cm2 were applied to 
volunteers respectively. This dose is included in the usual range of thickness 
application for sunscreens (0.5–1 mg of cream per cm2 of skin), which is 
usually below the recommended dose for a maximum sun protection 2 
mg/cm2 (KFDA, 2015). After an hour, the volunteers washed with a soap 
their arms. Blood and urine samples were monitored over 72 h and the first 
samples (T0) before exposure were collected. The volume of each urine 
samples were measured and all samples were stored at -70 °C until analysis.
The study was approved by the Seoul National University Institutional 
Review Board (SNUIRB # 1508/001-007). All participants were informed 





3.1.1 Blood sample preparation
The blood samples were prepared by the enzyme hydrolysis method as 
previously described (Lee et al., 2013; Dewalque et al., 2014; Ko et al., 2015)
with a minor modification. In brief, 500 	L of an aliquot of serum was mixed 
with 10 	L of the internal standard solution 13C6-BP-3, and 100 	L of 1 M 
ammonium acetate was added. The enzymatic treatments were performed by 
adding 20 	L of -glucuronidase/sulfatase and samples were incubated for 2 
h at 37 °C. The samples were acidified using 2 mL of 0.1 M formic acid and
loaded on the solid phase extraction (SPE) cartridge, Oasis HLB (polymeric 
reversed phase, 30 mg/3cc; Waters, Milford, MA), which had been 
conditioned with 3 mL of acetonitrile and 3 mL of deionized water. Absorbed 
BP-3 and metabolites were washed with 10% methanol and dried for 30 min 
at room temperature, and then eluted with 3 mL of methanol. The eluates 
were evaporated until dryness under a nitrogen flow and reconstituted in 100 
uL of a 70:30 (v:v) water-methanol solution. Concentrations of unconjugated
BP-3 in serum were determined following the same methodology described 
above without the enzymatic hydrolysis step.
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3.1.2 Urine sample preparation
The urine samples were measured using an automatic, high throughput 
online SPE-UPLC-MS/MS method for measuring BP-3 in urine. Sample
preparation was performed by following the method as previously described 
with some modifications (Ye et al., 2005, 2006). Briefly, 
	L of an aliquot 
of urine was mixed with 10 	L of the internal standard solution 13C6-BP-3, 
and 100 	L of 1 M ammonium acetate was added. The enzymatic treatments 
were performed by adding 20 	L of -glucuronidase/sulfatase and samples 
were incubated for 2 h at 37 °C. The samples were acidified using 100 	L of 
0.1 M formic acid, and then centrifuged at 10000 rpm for 10 min. The 
supernatants were transferred to insert and confirm the bubble. 
Concentrations of unconjugated BP-3 in urine were determined following the 
same methodology described above without the enzymatic hydrolysis step.
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3.2. UPLC-MS/MS analysis
Measurement of BP-3 and the metabolites in serum was performed by 
UPLC-MS/MS with Nexera autosampler and pump (Shimadzu, Kyoto,
Japan) coupled to API 4000 tandem mass spectrometer (AB Sciex, 
Framingham, MA) using a electrospray ionization source in negative mode 
(ESI ). The compound specific MS/MS parameters are shown in the 
supplementary information (Table S1). The chromatographic separation was 
carried out on a Capcell pak ACR column (2.0 × 150 mm, 3 um) from 
Shiseido Co., LTD (Tokyo, Japan) using gradient mode. The mobile phase 
composition was optimized by binary water (solvent A) and methanol
(solvent B). Gradient condition was as follow; 0.0-2.5 min, 10% B; 2.5-3.5
min, 10%-100% B; 3.5-8.0 min, 100%-100% B; 8.6-13.0 min, 100%-10% 
min. The flow rate was 0.2 mL/min and 10 	L of each sample was injected 
into the UPLC system. 
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Measurement of BP-3 and the metabolites in urine was performed by on-
line SPE-UPLC-MS/MS with Nexera autosampler and pump (Shimadzu, 
Kyoto, Japan) coupled to API 4000 tandem mass spectrometer (AB Sciex, 
Framingham, MA) using a electrospray ionization source in negative mode 
(ESI ). The MS and electrospray ionization parameters were optimized 
separately for each analyte by direct infusion of standards using the Analyst 
1.5.2 software (AB Sciex). The SPE column was an Oasis HLB column (2.1 
× 20 mm, 5 um) from Waters, (Milford, MA). The chromatographic 
separation was carried out on a Capcell pak ACR column (2.0 × 150 mm, 3 
um) from Shiseido Co., LTD (Tokyo, Japan) using gradient mode. The 
mobile phase composition was optimized by trinary water (solvent A), 
methanol (solvent B), 10% methanol (solvent C). Gradient condition was as 
follow; 0.0-2.5 min, 10% B; 0-2.5min, 0.2 ml/min, C; Left valve, 0; 2.5-
2.6min, 0 ml/min, C; 2.5-3.5 min, 100% B; 2.6-7.5min, 0 ml/min, C; 7.5-
7.6min, 0.2 ml/min, C; 8.5 min, Left valve, 1; 3.5-8.5min, 100% B; 8.5-
8.6min, 10%B; 8.6-13min, 100%-10%B. The flow rate was 0.2 mL/min and 
	L of each sample was injected into the UPLC system. Quantitation was 
based on peak areas relative to the stable isotope-labeled internal standards. 
Because the dosing substance in this study was deuterium-labeled BP-3 (BP-
3-d5) and BP-1 (BP-1-d5), we used 13C6-labeled-BP-3 as an internal standard.
Quality control measures were performed during every sample set, including 
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the analysis of blank, standard-spiked samples (spiked-QC) and pooled 
human serum or urine samples from this study (pooled-QC) was carried out 
during every sample set. In blank, any labeled analytes were not observed as 
a quantifiable level. For all analytes and both of the biological samples, the 
recovery in the spiked-QC samples was between 90.5% and 112.5% and the 
relative standard deviation (RSD) was 0.8% to 11.6%. The coefficient of 
variation for pooled-QC samples varied from varied from 0.3 % to 14.7 %. 
Calibration curve, ranging from 0.2 to 100 ng/mL, was plotted based on 
logarithmic ratio of the peak area of BP-3 and BP-1 to the peak area of the 
internal standard versus the logarithm of the BP-3 and BP-1 concentration 
(Yoon et al., 2015), whose regression coefficient (R) was >0.999 in urine, 
and (R) was >0.99 in serum. The limit of quantitation (LOQ) were
determined based on the lowest point where the logarithm form of calibration 
curve, consisting of very low concentrations, became the straight line, and 




Pharmacokinetic calculations were performed on each individual set of data
using the pharmacokinetic calculation WinNonlin (Pharsight, St.Louis, MO, 
U.S.A.) by non-compartmental method. Several descriptive pharmacokinetic 
parameters, such as maximal concentration (Cmax), peak time (Tmax), area 
under the curve (AUC) and mean residence time (MRT), were estimated. 
The fractional urinary excretion (Fue) was calculated based on the amount of 
total BP-3 excreted in urine over 72 h divided by single dermal application 
dose.
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4.2. Development of the pharmacokinetic model
As shown in Fig. 2, multi-compartment model was constructed to describe
the pharmacokinetic properties of BP-3 in human after a single dermal 
application. The transdermal modeling was performed by permeation 
coefficient (kp) obtained from the transdermal experiment and the skin-
vehicle. and Fick's diffusion model was applied to percutaneous exposure 
(Corley, 2000; Brown et al., 1989). The rate of absorption, distribution, 
metabolism, and excretion was assumed to be first-order kinetics. The 
constructed model was fitted into the time-concentration profile in serum and 
urine from five participants using Berkeley Madonna (University of 
California, Berkeley, CA, U.S.A.). The calibrated model was validated by 
evaluating the model prediction using urine data from other study.
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Figure 2. Structure of the pharmacokinetic model for BP-3 and its
metabolites after dermal application. Abbreviations: kp – The rate of 
absorption of BP-3 to skin (KFDA, 2016); ka –absorbed skin dose of BP-3
to central compartment; k12 – BP-3 disposition from central compartment to 
peripheral compartment; k21 – reabsorption from peripheral compartment to 
central compartment; k10 – unconjugated BP-3 elimination at central 
compartment; km1 – conjugated BP-3 formation in blood; km1u – conjugated 





Five healthy males participated in the study, and demographic 
characteristics are presented in Table 1. The respectively average age, height, 
body weight and body mass index (BMI) of the subject were 24 years (range 
20-28), 174 cm (range 163-182), 72 kg (range 62-89) and 24 (range 20-28). 








A 25 182 67 20
B 28 167 62 22
C 26 163 72 27
D 20 177 89 28
E 20 181 71 22
Mean ± SD 24 ± 4 174 ± 9 72 ± 10 24 ± 4
All participants were male (n=5). 
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2. Pharmacokinetic characteristics of benzophenone-3 and its
metabolites
The semilogarithmic plot of time-concentration profile for BP-3 and its 
metabolites in serum is shown in Fig. 3. After a single application with a
cream containing 5% BP-3, total BP-3, unconjugated BP-3 and total BP-1
present a similar profile. The serum concentrations of BP-3 and its 
metabolites increased 4 hours. From this point, BP-3 and its metabolites 
concentration decreased. The early phase with a rapid decline until 12 hours, 
and the second phase with a gradual and slow decline until 72 hours.
Following these decline phase, the structure of the model was determined as 
a multi-compartment model.
Plots of serum concentrations of total, unconjugated BP-3 and total BP-1 at 
each time point following dermal application were analyzed using model-
independent pharmacokinetic analysis. As shown in table 2, the mean Tmax
of unconjugated BP-3 (3.00 ± 0.71 h) was earlier than total BP-3 (3.20 ± 
1.10) and total BP-1 (4.00 ± 2.35). The mean Cmax, AUC0-, and AUMC0-of 
unconjugated BP-3 were similar to total BP-1, whereas unconjugated BP-3
was about 2-fold lower than total BP-3. The terminal half-life (T1/2) was 
calculated by dividing MRTlast by 1.44 (Boroujerdi, 2001). Parameter of 
unconjugated BP-3 was longer than total BP-3 and BP-1. CLt, total body
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clearance was estimated using an equation, (CLt)dermal = F x D / AUC, where F 
is bioavailability and D is applied dose, bioavailability, the fraction of an applied 
dose that reaches the systemic circulation was assumed as 1.16% (SCCP, 2006). 
The total body clearance of BP-3 was 17.1 L/h. 
Time [hr]
























Figure 3. Time-concentration profile for BP-3 in serum. Each point and error
bar represents the arithmetic mean and the standard deviation of volunteers 
(n=5). Concentrations below LOD were excluded.
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Table 2. Pharmacokinetic parameters for benzophenone-3 in serum.
Parameter Unconjugated BP-3 Total BP-3 Total BP-1
Tmax (h) 3.00 ± 0.71 3.20 ± 1.10 4.00 ± 2.35
Cmax (nM) 32.7 ± 7.53 70.9 ± 27.8 39.0 ±14.8
AUC0- (nM·h) 336 ± 90.5 619 ± 156.3 361 ±76.9
AUMC0- (nM·h2) 7035 ± 3704 4913 ±2807
MRTlast (h) 11.2 ± 5.91 12.9 ±5.69
T1/2 (h) 9.06 ± 4.20 7.77 ± 4.11 8.93 ±3.95
Each value is revealed as arithmetic mean ± standard deviation of
participants. Tmax, peak time; Cmax, peak concentration; AUC0-, area under the 
serum concentration-time curve between 0 and ; AUMC0-, area under first-





Cumulative urinary excretion of BP-3 and its metabolites were presented in 
Fig. 4. BP-3 was mainly excreted as a metabolized form rather than
unconjugated form. The fractional urinary excretion (Fue, %) of total BP-3
was an average of 0.77% (range: 0.53~1.07%). The average Fue of 
unconjugated BP-3 was 0.0013% (range: 0.0005~0.0019%), and the 
average Fue of total BP-1 was 0.19% (range:0.09~0.41%). 
Time [hr]

































Figure 4. Accumulated amount of BP-3 recovered in urine. Each point and
error bar represents the arithmetic mean and the standard deviation of 
volunteers (n=5). Concentrations below LOD were excluded.
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3. Pharmacokinetic modeling
The multi-compartment model optimization for BP-3 and its metabolites 
was conducted (Fig. 5, 6). The model represented good prediction for time-
concentration profile of BP-3 and its metabolites. Using this model, we 
determined the pharmacokinetic parameters, as shown in table 3. 
four females (n=11). The kinetic parameters were fixed and applied dose, 
exposure body area, exposure duration were altered. The model validation is
presented in Fig. 7.
(2002) with a single dermal application of 2mg/cm2 of BP-3 to seven males,










































































Figure 5. Model optimization using serum concentration. (A) unconjugated
BP-3; (B) total BP-3; (C) total BP-1 in serum. Each point and error bar
represent arithmetic mean ± standard deviation of participants. Solid line 


































































































Figure 6. Model optimization using cumulative urinary excretion amount.
(A) unconjugated BP-3; (B) total BP-3; (C) total BP-1 in urine. Each point 
and error bar represent arithmetic mean ± standard deviation of participants. 
Solid line reveals multi-compartment model fit to the data. Concentrations 
below LOD were excluded.
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Table 3. Pharmacokinetic parameter estimates from multi-compartment model.
Parameter Notes Value
Ka, /h Skin amount  0.39
K12, /h Central compartment  8.67
K21, /h Peripheral compartment  0.07
K10, /h unconjugated BP-3 elimination from blood via urine 0.02
Km1, /h unconjugated BP-3 !"-3 formation 15.0
Km2, /h unconjugated BP-3 $"-1 formation 0.95
Km1u, /h Conjugated BP-3 elimination from blood via urine 5.98
Km2u, /h Total BP-1 elimination from blood via urine 6.50
Vpb, L Volume of distribution for unconjugated BP-3 1.02
Vm1, L Volume of distribution for Conjugated BP-3 2.30
Vm2, L Volume of distribution for Total BP-1 0.17
Vt, L Volume of distribution for Total BP-3 1.90
31
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* * * *
*** * *******
Figure 7. Model validation. Each point and error bar represent arithmetic
mean and standard deviation of Gonzalez (2002)’s eleven volunteers (seven 
males and four females). Star symbols are maximum values of volunteer. 
Solid line represents multi-compartment model fit to the data.
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. Discussion
Benzophenone-3 (BP-3) is a chemical blocking agent that blocks ultraviolet 
light. It is mainly used in sunscreen agents and functional cosmetics and is 
mostly exposed to the skin. Several studies have reported the possibility of
endocrine disturbance, while pharmacokinetic data or model for BP-3 in 
humans were limited. For this reason, we represented the skin using a more 
empirical compartment model. In the present study, we investigated the time 
profiles of BP-3 and its metabolites in serum and urine after dermal 
application from a controlled dosing study. Based on the observations, a 
human PK model, which is composed of a multi-compartment, was 
developed to describe absorption, distribution, metabolism and elimination 
of BP-3 following dermal exposure.
BP-3 is widely used in commercial sun protection products at a maximum 
shown that consumers apply much less than this typically between 0.5 and 
1.5 mg/cm2 (Diffey et al., 2001). We considered the legal standards, the 
thickness, amount of the area and formulation of sunscreen that people 
commonly use. In this study, cream (200 mg) of containing 5% BP-3 were 
exposed to the forearm (200 cm2) for 1 hour. After dermal application of 
3 is regulated below 2 mg/cm2 (KFDA, 2015). A  number  of  studies  have
concentration of 5% for BP-3 and the maximum formulation standard of BP-
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BP-3, they may be absorbed and accumulated in the body. They pass through 
the skin and reach the kidneys, where they are metabolized and further 
excreted. Urine is the primary route, with feces being the secondary route for 
elimination of both parent compounds and metabolites. Toxicity studies on 
human plasma and urine samples revealed o-dealkylation of the methoxy
side chain to be the major pathway of BP3 metabolism. This mechanism 
yields the most abundant metabolite, 2,4-dihydroxybenzophenone (BP-1).
Aromatic hydroxylation is a secondary pathway, in which metabolites 2,3,4-
trihydroxybenzophenone (THB) and 2,2-dihydroxy-4-methoxy-benzophenone
(BP-8) are formed (Díaz-Cruz et al., 2008). And BP-8 was detected in trace
amounts in urine samples, but copious amounts were detected in fecal 
samples (Okereke et al., 1994). In the case of BP-3, studies in rats have 
reported substantial dermal metabolism, protein binding and excretion in 
both urine (67%) and feces (21%) with other studies reporting excretion in 
breast milk (Jiang et al., 1999). In order to investigate of BP-3
pharmacokinetic characters, except BP-8 which is mainly detected in feces, 
this study analysis BP-3 BP-1 and THB in bio-samples. However, in the case 
of THB, THB could not be analyzed as the analysis method of this study. 
Therefore, only BP-3 and BP-1 were measured in this study.
The semilogarithmic plot of time-concentration profile in serum (fig.3)
demonstrated that the pharmacokinetics of BP-3 could be explained by a 
multi-compartment model. The volume of distribution for central 
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compartment (Vpb) was 1.02 L, for conjugated BP-3 was 2.30, for total BP-
1 was 0.17 L and that for total BP-3 was 1.90 L. Consist of the model rate 
constants were assumed to follow first-order kinetics. After a single 
application with a cream containing 5% BP-3, BP-3 was permeated to skin 
using kp and then BP-3 in skin was distributed to central compartment 
(ka=0.39). Unconjugated BP-3 in central compartment was rapidly 
distributed to peripheral compartment (k12=8.672), whereas slowly 
redistributed to central compartment (k21=0.071). Unconjugated BP-3 was 
eliminated in urine (k10=0.02). Unconjugated BP-3 was conjugated such as 
BP-3-glucuronide and BP-3-surfate (km1=15.03), which were rapidly 
excreted in urine because of increased in water solubility (km1u=5.98). And 
Unconjugated BP-3 was metabolized into BP-1 (km2=0.95), which were 
rapidly excreted in urine (km2u=6.50).  
Cumulative urinary excretion of total BP-3 as shown in Fig. 4 provided that 
an average of 0.77% of applied BP-3 was excreted in urine. Gonzalez (2002) 
had previously performed similar work to this study. Containing 4% BP-3
lotion applied to 11 participants (7 males, 4 females). They applied it over 
the whole body (except for the scalp and genital areas). And participants put 
on their normal clothes after the lotion was absorbed to the skin. And then, 
they could shower only once, after 12 hours during 48 hours period. The 
average total amount excreted in urine approximately 0.5% of the applied 
amount of BP-3. To validated the our PK model, we used to Gonzalez et al.,
35
(2002) recoverd amount data of BP-3 in urine. As shown in Fig. 7., Model 
fitness results show that cumulative urine data of BP-3 was fitted within 
standard deviation and maximum observed data. But early preliminary time 
point didn’t fit well. Gonzalez data shown that BP-3 absorption was delayed 
as like lag time. Lag time that is a function of the drug loading the stratum 
corneum and dermis, diffusivity, and thickness of the skin (Lazaridis et al.,
2010). The reason is that previous study and this study were used dermal 
application of different type such as lotion versus cream. And race also 
different. Another study is that Hayden, Roberts and Benson reported on the 
systemic absorption in humans of BP-3 after topical application. Analysis of 
the urine using -glucuronidase suggests that BP-3 and its metabolites 
undergo extensive conjugation in the body. It is estimated that the actual 
amount absorbed from the applied formulation over 10 hours period was 
between 1 and 2% of the applied amount contained in the product. This study 
also performed analysis of the urine using -glucuronidase plus sulfatase. In 
order to excrete in urine, Almost of the BP-3 and BP-1 in urine undergo 
conjugation or demethylation. And the fraction of urinary excretion for 
conjugated BP-3 (0.76%) was 4-fold upper than total BP-1 (0.19%), which 
was approximately 580-fold upper than unconjugated BP-3 (0.0013%).
One of limitation of the study is that we don’t know how much cream of 
BP-3 are absorbed. Therefore, we estimated how much was absorbed into 
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, it is 
absorbed by the skin to about 5 ± 1% of the absorption by ingestion. Another 
limitation of the study is that study population. The pharmacokinetic model 
for BP-3 is constructed based on a specific population as healthy male. And
the model validation was only performed using the data from Gonzalez et al.,
(2002). Additional model validation processes using data in blood are needed 
in order to verify universal applicability of the model. And pharmacokinetic 
model in the study can’t take account of all situation about using sun screen. 
We performed to dermal application during only 1 hour and single exposure, 
whereas people usually applied it all day or more than eight hours. And some 
people apply it several times a day. In spite of the limitations, a quantitative 
knowledge on human pharmacokinetic of BP-3 is essential to investigate BP-
3 exposure using biomonitoring data. Simple pharmacokinetic model is used 
to reverse dosimetry by biomonitoring data and evaluate risk assessment. In 
risk assessment, using pharmacokinetic model instead of estimated equation
might reduce uncertainties (US EPA, 2002).
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. Conclusions
In conclusion, the present study determined the time-concentration profiles 
of BP-3 in human serum and urine after a single dermal application, and 
estimated pharmacokinetic parameters through non-compartmental analysis. 
Furthermore, it was found that the multi-compartment model constructed 
based on the profiles well described the pharmacokinetic characteristics of 
BP-3. This study provides pharmacokinetic data of BP-3, which help to 
understand the absorption, distribution, metabolism and excretion of BP-3 in 
human body after topical application. Moreover, despite the need for further 
validation in serum process, the human pharmacokinetic model for BP-3 can 
be a useful tool for reconstructing exposure dose of BP-3 by applying human 
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